NEW YORK, May 26, 2011 Reportlinker.com announces that a new market research report is available in its catalogue:
The Drug-Eluting Stent Market Outlook to 2016
Advertisement
http://www.reportlinker.com/p0483600/The-Drug-Eluting-Stent-Market-Outlook-to-2016.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology
Advertisement
Introduction
The DES market has seen tremendous growth since the introduction of DES in 2003, but the market suffered setbacks in 2007 on the release of clinical data that indicated a link to increased thrombosis. Sales of DES have since stabilized owing to the introduction of novel stents with proven superior therapeutic properties over the traditional bare metal stent.
Features and benefits
* Assess the major market trends including mergers and acquisitions, and licensing agreements and their impact on the market.
* Identify the growth strategies of the leading market players and their likely impact on the future DES market.
* Identify key innovations that will shape the DES market of the future.
* Gain insight into the influence of the emerging economies in determining the present and future DES market size.
* Identify emerging companies that are likely to compete in the near future with the leading DES manufacturers.
Highlights
The DES market has been traditionally characterized by low levels of innovation. However, with the shift in hospital purchasing models from the current sole-supplier model to the capitation pricing model, innovative products are the only ones likely to command premium prices. Thus, this will increase the level of innovation in this segment.
The DES markets in India and China are set to undergo growth in the next five years, concurrent with the improvement of the economies of these two countries and the introduction of the 'Healthy China 2020' plan. However, leading players face stiff competition from local companies in these regions.
Hospitals are currently entering into preferred-supplier agreements whereby they source their medical device requirements from one or two preferred suppliers to leverage volume-based discounts. This puts large suppliers such as Boston Scientific in an advantageous position as they can cater to consolidated spend categories.
Your Key questions answered
* What are the innovations being made in DES technology which of these offers significant potential for future growth?
* What are the key industry trends in terms of mergers and acquisitions and contractual and licensing agreements between buyers and suppliers?
* What are the key regulations in the DES segment and what is the possible impact of new DES technology on the product approval process?
* How have the leading players built a strong position in the DES market and what are their future growth strategies?
* Who are the emerging players in the DES market, what threat do they pose, and what are their business expansion strategies?
TABLE OF CONTENTS
Executive Summary
About Business Insights
Disclaimer
Overview of the global drug-eluting stents market
DES market landscape
Innovations in the DES market
Key players in the DES market
Overview of the global drug-eluting stents market
Summary
Introduction
Position of DES within the cardiac device market
Evolution of DES
Advantage of DES
Market size and forecasts of DES
Historical market size and forecasts
Geographical segmentation
Epidemiology of major cardiovascular diseases
Adoption trends in cardiovascular procedures
Growth drivers
Increased adoption by physicians owing to prevention of late in-stent restenosis
Decreased need for repeat procedures
Demographics - rise in the mean age of the population
Lifestyle changes - increased prevalence of obesity
Growth resistors
High cost of DES compared with BMS
Release of adverse clinical data pertaining to late stent thrombosis
Release of COURAGE data indicating no significant advantage of DES over BMS
Problems associated with Medicare reimbursement of DES
Regulatory changes impacting the DES market
DES market landscape
Summary
Introduction
Market trends
Mergers and acquisitions
Important mergers and acquisitions by leading players
Mergers, acquisitions, and co-exclusivity agreements among emerging players
Preferred supplier agreements
Increased importance of emerging countries
Pricing of DES
Historical prices of DES and trends
Future trends in pricing
Pricing in emerging economies
US Medicare Part A reimbursement costs of DES
Cost-effectiveness of DES versus BMS
Licensing agreements between pharmaceutical companies and DES manufacturers
Innovations in the DES market
Summary
Introduction
Factors driving innovation
Major innovations
Innovations in the polymer component of DES
Drug-coated balloons
Bifurcation stenting
Self-expandable DES
Development of DES with a two-drug offering
Drugs used in DES
New product approvals
FDA approvals
CE mark approvals
Pipeline
Nevo sirolimus-eluting stent (Johnson & Johnson)
Promus and Taxus everolimus-eluting element stents (Boston Scientific)
Taxus Petal paclitaxel-eluting stent (Boston Scientific)
Odyssey (Boston Scientific)
XIENCE Nano (Abbott labs)
Protex coronary stent system (Nexeon MedSystems)
CoroflexDEBlue stent (B. Braun Melsungen)
Key players in the DES market
Summary
Introduction
Relative positioning of the leading market participants
Boston Scientific
Abbott Laboratories
Cordis (Johnson & Johnson)
Medtronic
Product growth and share snapshot
Emerging players
Relative positioning of the emerging market participants
Opto Circuits
Sahajanand Medical Technologies
Blue Medical Devices
Biosensors International
Stentys
MicroPort Scientific
Orbus-Neich Medical
Appendix
Scope
Methodology
Glossary/Abbreviations
References
To order this report:
Drug Delivery Technology Industry: The Drug-Eluting Stent Market Outlook to 2016
Drug Delivery Technology Business News
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
